XML 33 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
Restructuring and Related Charges
 12 Months Ended
Dec. 29, 2017
Restructuring and Related Activities [Abstract]  
Restructuring and Related Charges
7.
Restructuring and Related Charges
During fiscal 2013, the Company launched a restructuring program designed to improve its cost structure ("the 2013 Mallinckrodt Program"). The 2013 Mallinckrodt Program included actions across the Specialty Brands, Specialty Generics and former Global Medical Imaging segments, as well as within corporate functions. The Company expected to incur charges of $100.0 million to $125.0 million under this program as the specific actions required to execute on these initiatives were identified and approved. The 2013 Mallinckrodt Program is substantially complete.
In July 2016, the Company's Board of Directors approved a $100.0 million to $125.0 million restructuring program ("the 2016 Mallinckrodt Program") designed to further improve its cost structure, as the Company continues to transform its business. The 2016 Mallinckrodt Program is expected to include actions across the Specialty Brands and Specialty Generics segments, as well as within corporate functions. There is no specified time period associated with the 2016 Mallinckrodt Program.
In addition to the 2016 Mallinckrodt Program and the 2013 Mallinckrodt Program, the Company has taken restructuring actions to generate synergies from its acquisitions.
Net restructuring and related charges by segment from continuing operations are as follows:
 
Fiscal Year Ended
 
Three Months Ended
 
December 29, 2017
 
September 30, 2016
 
September 25, 2015
 
December 30, 2016
Specialty Brands
$
25.4

 
$
23.3

 
$
36.5

 
$
2.6

Specialty Generics
7.7

 
3.4

 
4.5

 
0.8

Corporate
3.3

 
11.5

 
4.3

 
1.9

Restructuring and related charges, net
36.4

 
38.2

 
45.3

 
5.3

Less: accelerated depreciation
(5.2
)
 
(4.9
)
 
(0.3
)
 
(1.5
)
Restructuring charges, net
$
31.2

 
$
33.3

 
$
45.0

 
$
3.8


Net restructuring and related charges by program from continuing operations are comprised of the following:
 
Fiscal Year Ended
 
Three Months Ended
 
December 29, 2017
 
September 30, 2016
 
September 25, 2015
 
December 30, 2016
2016 Mallinckrodt Program
$
36.2

 
$
8.3

 
$
—

 
$
5.2

2013 Mallinckrodt Program
(0.7
)
 
26.2

 
12.0

 
—

Acquisition programs
0.9

 
3.7

 
33.6

 
0.1

Other programs
—

 
—

 
(0.3
)
 
—

Total programs
36.4

 
38.2

 
45.3

 
5.3

Less: non-cash charges, including impairments and accelerated share based compensation expense
(5.2
)
 
(4.9
)
 
(10.1
)
 
(1.5
)
Total charges expected to be settled in cash
$
31.2

 
$
33.3

 
$
35.2

 
$
3.8


Non-cash charges in fiscal 2015 include $9.8 million of accelerated share based compensation expense related to employee terminations, primarily related to the acquisition of Questcor Pharmaceuticals, Inc. ("Questcor") in fiscal 2014.
The following table summarizes cash activity for restructuring reserves, substantially all of which related to employee severance and benefits and exiting of certain facilities:
 
2016 Mallinckrodt Program
 
2013 Mallinckrodt Program
 
Acquisition Programs
 
Other Programs
 
Total
Balance at September 26, 2014
$
—

 
$
26.6

 
$
7.9

 
$
0.4

 
$
34.9

Charges from continuing operations
—

 
11.7

 
25.3

 
—

 
37.0

Charges from discontinued operations
—

 
4.7

 
—

 
—

 
4.7

Changes in estimate from continuing operations
—

 
—

 
(1.5
)
 
(0.3
)
 
(1.8
)
Changes in estimate from discontinued operations
—

 
(8.9
)
 
—

 
—

 
(8.9
)
Cash payments
—

 
(22.5
)
 
(21.7
)
 
(0.1
)
 
(44.3
)
Reclassifications (1)
—

 
(3.0
)
 
—

 
—

 
(3.0
)
Currency translation
—

 
(0.6
)
 
—

 
—

 
(0.6
)
Balance at September 25, 2015
—

 
8.0

 
10.0

 
—

 
18.0

Charges from continuing operations
6.4

 
24.6

 
5.0

 
—

 
36.0

Charges from discontinued operations
—

 
2.5

 
—

 
—

 
2.5

Changes in estimate from continuing operations
—

 
(1.4
)
 
(1.3
)
 
—

 
(2.7
)
Changes in estimate from discontinued operations
—

 
(0.3
)
 
—

 
—

 
(0.3
)
Cash payments
(0.2
)
 
(20.3
)
 
(13.2
)
 
—

 
(33.7
)
Reclassifications (1)
—

 
(1.3
)
 
—

 
—

 
(1.3
)
Balance at September 30, 2016
6.2

 
11.8

 
0.5

 
—

 
18.5

Charges from continuing operations
3.7

 
—

 
0.1

 
—

 
3.8

Cash payments
(0.4
)
 
(6.7
)
 
(0.4
)
 
—

 
(7.5
)
Balance at December 30, 2016
9.5

 
5.1

 
0.2

 
—

 
14.8

Charges from continuing operations
35.8

 
—

 
0.9

 
—

 
36.7

Changes in estimate from continuing operations
(4.8
)
 
(0.7
)
 
—

 
—

 
(5.5
)
Cash payments
(26.1
)
 
(4.4
)
 
(0.3
)
 
—

 
(30.8
)
Reclassifications (1)
0.3

 
—

 
—

 
—

 
0.3

Balance at December 29, 2017
$
14.7

 
$
—

 
$
0.8

 
$
—

 
$
15.5


(1)
Represents the reclassification of pension and other postretirement benefits from restructuring reserves to pension and postretirement obligations.

Net restructuring and related charges, including associated asset impairments, incurred cumulative to date related to the 2016 and 2013 Mallinckrodt Programs are as follows:
 
2016 Mallinckrodt Program
 
2013 Mallinckrodt Program
Specialty Brands
$
32.5

 
$
18.8

Specialty Generics
9.1

 
18.3

Discontinued Operations (including Nuclear and CMDS)
—

 
69.9

Corporate
9.0

 
17.7

 
$
50.6

 
$
124.7


Substantially all of the restructuring reserves are included in accrued and other current liabilities on the Company's consolidated balance sheets.